Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders (2017 - 2026)

Takeda Pharmaceutical's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$2.3 billion for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 388.62% year-over-year to -$2.3 billion in Q1 2026; TTM through Mar 2026 was -$2.6 billion, a 222.13% decrease from a year earlier, with the FY2026 full-year figure at -$1.0 billion, down 242.88% from the prior year.
• Net Income towards Common Stockholders rose to -$2.3 billion in Q1 2026 per TAK's latest filing, from -$2.4 billion in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $1.5 billion in Q3 2025 and bottomed at -$2.4 billion in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is $642.4 million (2024), against an average of $279.8 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 912.2% in 2023 and tumbled 422.64% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $843.2 million in 2022, then plunged by 75.05% to $210.4 million in 2023, then tumbled by 422.64% to -$678.8 million in 2024, then tumbled by 252.64% to -$2.4 billion in 2025, then increased by 1.85% to -$2.3 billion in 2026.
• Per Business Quant, the three latest TAK Net Income towards Common Stockholders figures stand at -$2.3 billion (Q1 2026), -$2.4 billion (Q4 2025), and $1.5 billion (Q3 2025).